CanariaBio Participates in 'Bio Europe'... Discusses Follow-up Licensing Rights in Europe and Beyond

Canaria Bio announced on the 3rd that it will participate in BIO-EUROPE 2023, Europe's largest partnering event held in Munich, Germany from the 6th to the 8th of this month (local time), to discuss licensing agreements for the ovarian cancer immuno-oncology drug "Oregovomab" with over 30 multinational pharmaceutical companies.

Canaria Bio recently signed exclusive sales and license agreements for Oregovomab in a total of seven countries in the Southeast Asia region, including Australia and New Zealand, following the Middle East and North Africa (MENA) region.

CEO Nahanik said, "In the first quarter of next year, we will analyze the final results of the global Phase 3 clinical trial cohort 2," adding, "If the results are favorable, we plan to start selling Oregovomab through the Early Access Program before FDA approval." He explained that their participation in this event was also aimed at selecting regional partners for this purpose.

Meanwhile, the ovarian cancer immuno-oncology drug Oregovomab showed a progression-free survival (PFS) of 42 months in Phase 2 clinical trials, which is 30 months longer than the existing standard treatment. Additionally, the hazard ratio for overall survival (OS) was 0.35, significantly better than the PFS hazard ratio of 0.46. Currently, Canaria Bio is developing the ovarian cancer treatment Oregovomab through its wholly-owned subsidiary Canaria Bio (formerly MHC&C).

This content was produced with the assistance of AI translation services.